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Objective: We have previously shown that the transcription factor, nuclear factor of
activated T-cells 5 (NFAT5), regulates vascular smooth muscle cell phenotypic modulation,
but the role of NFAT5 in atherosclerosis is unknown. Our main objective was to
determine if NFAT5 expression in bone marrow (BM)-derived cells altered atherosclerotic
development and macrophage function. Methods and Results: NFAT5+/−ApoE−/− mice
were generated for in vivo atherosclerosis studies. Following high fat diet feeding, en face
analysis of the thoracic aorta established that genome-wide NFAT5 haploinsufficiency
reduced atherosclerotic lesion formation by 73%. BM transplant studies revealed that
transplantation of NFAT5+/−ApoE−/− marrow into NFAT5+/+ApoE−/− mice resulted in
a similar 86% reduction in lesion formation. In vitro functional analysis of BM-derived
macrophages demonstrated that NFAT5 is required for macrophage migration, which
is a key event in the propagation of atherosclerosis. Conclusion: We have identified
NFAT5 in BM-derived cells as a positive regulator of atherosclerotic lesion formation and
macrophage function in the vasculature.
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INTRODUCTION
Nuclear factor of activated T-cells 5 (NFAT5/tonicity-responsive
enhancer binding protein) is a Rel homology transcription fac-
tor that is critical for the regulation of various cellular functions
in both hypertonic and isotonic environments (Miyakawa et al.,
1999; Woo et al., 2002; Halterman et al., 2011a). NFAT5 is tradi-
tionally known for its hypertonicity-induced activation in tissues
that experience large fluxuations in tonicity, such as the kidney
(Miyakawa et al., 1999), where hypertonic conditions enhance
NFAT5 expression, transactivation, and binding to target genes
that control cellular homeostasis (Handler and Kwon, 2001). In
tissues that do not undergo large fluctuations in tonicity such
as the vasculature, rheumatoid arthritic joints, and carcinomas,
various tonicity-independent stimuli have been identified as reg-
ulating NFAT5 expression and activity (Jauliac et al., 2002; Yoon
et al., 2011; Halterman et al., 2011b). Previous studies in our lab
were the first to describe NFAT5 function in the vasculature, and
our research has identified a hypertonicity-independent role for
NFAT5 in vascular smooth muscle cell (SMC) phenotypic mod-
ulation (Halterman et al., 2011b). Additionally, we showed that
NFAT5 protein was elevated in ApoE−/− mouse atherosclerotic
lesions following a 20-week high fat diet (HFD; Halterman et al.,
2011b). However, the role of NFAT5 in chronic atherosclerotic
vascular disease is unknown.
Cardiovascular disease is the number one cause of morbidity
and mortality worldwide, and atherosclerosis contributes to vas-
cular disease by increasing the risk of vessel occlusion, myocardial
infarction, and stroke (Roger et al., 2011). Atherosclerotic
lesion formation is propagated by endothelial cell (EC) dys-
function, cholesterol accumulation in the vessel wall, mono-
cyte/macrophage adhesion and migration into the lesion, and
SMC formation of a protective fibrotic cap (Lusis, 2000).
Although the function of NFAT5 in atherosclerosis is undeter-
mined, NFAT5 regulation in SMCs, ECs, and macrophages has
been previously identified outside of the context of vascular dis-
ease. Our prior studies show that NFAT5 is required for platelet-
derived growth factor BB and serum-induced SMC migration
(Halterman et al., 2011b), while others report that NFAT5 knock-
down inhibits EC survival and migration, and NFAT5+/− mice
have inhibited angiogenesis (Yoon et al., 2011). Research in
bone marrow-derived macrophages (BMDMs) highlights the role
of hypertonicity-induced NFAT5 activation (Morancho et al.,
2008), andNFAT5 protein inmacrophages regulates expression of
TNFα, VEGF-C, and TLR-induced antimicrobial genes (Machnik
et al., 2009; Roth et al., 2010; Buxade et al., 2012).
The main objective of our study was to determine how
genome-wide and bone marrow (BM)-specific NFAT5 haploin-
sufficiency altered atherosclerotic lesion formation. By utiliz-
ing NFAT5+/−ApoE−/− mice for HFD-induced atherosclerosis
studies, we found that genome-wide NFAT5 haploinsufficiency
inhibited atherosclerotic lesion development. Furthermore, bone
marrow transplant (BMT) of NFAT5+/−ApoE−/− BM into
NFAT5+/+ApoE−/− mice resulted in a similar impairment in
lesion development. These results provide evidence that NFAT5
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in BM-derived cells is critical for enhancing atherosclerosis. We
additionally show that BMDMs harvested from NFAT5+/− mice
have impaired migratory abilities, and we believe these findings
are noteworthy because macrophage migration into the lesion is
a key event in the propagation of atherosclerosis. In summary,
we have identified that NFAT5 in BM-derived cells accelerates
atherosclerosis, and we highlight the important role of NFAT5 in
the regulation of macrophage migration.
MATERIALS AND METHODS
ANIMALS
Animal protocols were approved by the University of Virginia
Animal Care andUse Committee. NFAT5+/−ApoE−/− mice were
generated through breeding ApoE−/− (The Jackson Laboratory)
and NFAT5+/− mice (gift from H. M. Kwon; Go et al., 2004).
HFD studies: 22 male littermates were placed on a HFD (by
weight 21% fat, 0.15% cholesterol, 19.5% casein, Harlan Labs)
for 20 weeks. BMT studies: 27 male NFAT5+/+ApoE−/− mice
underwent irradiation (600 RAD, twice). BM extracted from
the femurs and tibias of three male NFAT5+/+ApoE−/− donor
mice and three male NFAT5+/−ApoE−/− donor mice were spun
down, resuspended in RPMI media + 5% FBS, and 3 × 106
cells were injected via the tail vein into two groups of recip-
ient NFAT5+/+ApoE−/− mice. For proof of radiation efficacy,
2 NFAT5+/+ApoE−/− recipients did not receive bone marrow
and subsequently died. Following a 4-week recovery, recipient
mice were placed on a HFD for 16 weeks.
EN FACE
Thoracic aortas were fixed in 4% paraformaldehyde, cleaned of
all adipose and connective tissue, and stained with Sudan IV for
5min. The tissues were then longitudinally cut, pinned flat, and
imaged. Two different cameras had to be used to image aortas for
the first and second in vivo studies, which accounts for the slight
difference in images observed from one study to the next. Because
different cameras were used, we did not cross-analyze quantitative
en face data between the two studies. ImageJ software was used for
staining quantification.
IMMUNOHISTOCHEMISTRY
Aortic arches were fixed with 4% paraformaldehyde and embed-
ded in paraffin. Five micrometer sections were prepared for
staining with primary antibodies (mouse anti-SMαA [Santa
Cruz], mouse anti-MAC2 [Cedarlane]) or hematoxylin and eosin
(H&E). Sections cut at the center of the aortic arch (where most
lesions develop in the lesser curvature, around 200 um into the
tissue) were used for immunohistochemical staining and analysis.
In brief, after microwave Antigen Retrieval (Vector Laboratories;
with the exception of MAC2), primary antibodies were detected
using a Vectastain Elite Kit (Vector Laboratories) and DAB
(Dako Corp) for visualization. Harris Hematoxylin (Richard-
Allen Scientific) served as a counterstain. Negative controls were
run with the omission of the primary antibody.
TOTAL PLASMA CHOLESTEROLMEASUREMENT
Blood samples were collected for all mice at the conclusion
of HFD feeding. Samples were incubated with the Infinity
Cholesterol Reagent (Thermo Scientific) for 5min at 37◦C, and
absorbance was measured at 500 nm. All unknown samples were
calibrated to a sample of known concentration.
QUANTIFICATION OF IMMUNOHISTOCHEMISTRYAND VESSEL
MORPHOMETRY
Image-Pro Plus 7.0 software was used to quantify SMαA and
MAC2 staining in the lesion. ImageJ software was used to deter-
mine medial area (=external elastic lamina area-internal elastic
lamina [IEL] area) and lesion area (=IEL area-luminal area) from
H&E-stained aortic arch sections.
In vitro ASSAYS
BM was harvested from the femurs and tibias of 11–13 week-
old WT and NFAT5+/− mice. Bones were kept sterile, cut
at the ends, and placed into a needle-punctured 500μl cen-
trifuge tube set within a larger 1500μl tube. Following high-
speed centrifugation, extracted BM cells were treated with 0.83%
ammonium chloride to lyse red blood cells. The remaining BM
cells were plated onto 100mm dishes in RPMI Media 1640
(containing 1% antibiotic/antimycotic, 20mM Hepes, & 10%
FBS) plus the addition of macrophage colony stimulating factor
(M-CSF, Life, 30 ng/mL). Cells were kept in fresh media con-
taining M-CSF for a period of 7 days to differentiate the cells
into BMDMs. Adhesion assay: Human umbilical vein endothe-
lial cells (HUVECs) were plated in a 12-well and stimulated with
vehicle (diH2O, 10 ng/mL) or TNFα (Millipore, 10 ng/mL) in
M199 Media for 4 h. BMDMs pre-incubated with Calcein AM
(Life, 5μg) were added to wells containing stimulated HUVECs
for a 30-min incubation at 37◦. HUVECswere washed thoroughly
with PBS and fluorescence was quantified in a FLUOstar plate
reader to identify the amount of adherent BMDMs. Boyden cham-
ber migration assay: BMDMs in RPMI Media 1640 were plated in
the wells of a Costar Transwell (Fisher) and given 24 h to adhere
to the membrane. Cells were washed, and RPMIMedia 1640 con-
taining M-CSF (Life, 30 ng/mL) or vehicle (diH2O, 30 ng/mL)
was added to the bottom of the Transwell. Media without M-CSF
was added to the top. Cells were incubated for 24 h, washed, and
fixed in 4% paraformaldehyde. Cells on the top of the mem-
brane were scraped off with a sterile swab, and migrated cells
on the bottom of the membrane were stained with crystal vio-
let, imaged, and quantified using ImageJ software. Control wells
were not scraped to verify that BMDMs did originally adhere
to the membrane. BrdU proliferation assay: BMDMs in RPMI
Media 1640 were plated in a 24-well and allowed 24 h to adhere.
Cells were washed and RPMI Media 1640 containing M-CSF
(Life, 30 ng/mL) or vehicle (diH2O, 30 ng/mL) and BrdU (Roche,
10μm) was added for 24 h. Cells were then washed, fixed in
4% paraformaldehyde, incubated with an anti-BrdU-POD anti-
body + TMB substrate (Pierce), and absorbance was measured
on a FLUOstar plate reader to quantify cellular proliferation.
Engulfment assay: BMDMs in RPMI Media 1640 were plated in a
24-well and allowed 24 h to adhere. RPMI Media 1640 containing
FluoSphere Carboxylate Microspheres (Life, 4.5 × 106 beads per
well) was added to wells containing BMDMs for 30min. BMDMs
were thoroughly washed with PBS and fluorescence was quan-
tified to test for engulfment of FluoSpheres. Wells were imaged
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under a lightmicroscope to verify that no FluoSpheres had simply
adhered to the culture dish.
STATISTICAL ANALYSES
Statistical significance was confirmed through a t-test or One-
Way ANOVA (p < 0.05).
RESULTS
GENOME-WIDE NFAT5 HAPLOINSUFFICIENCY INHIBITS
ATHEROSCLEROTIC LESION FORMATION
Due to the perinatal lethality of our NFAT5−/− mice,
NFAT5+/−ApoE−/− mice were generated for atherosclerosis
studies. Aortic arches were harvested for immunohistochemi-
cal analysis, and descending thoracic aortas were stained with
Sudan IV and laid en face for lesion identification (Figure 1).
En face analysis identified that NFAT5+/−ApoE−/− thoracic
aortas displayed a 73% reduction in atherosclerotic lesion cov-
erage compared to NFAT5+/+ApoE−/− controls (Figure 2A).
Similarly, H&E staining of lesions in the lesser curvature of
the aortic arch identified a 43% reduction in lesion/media area
in NFAT5+/−ApoE−/− aortas (Figure 2B). Following 20 weeks
of HFD feeding, no difference was recorded in total choles-
terol or body weight between NFAT5+/−ApoE−/− and control
NFAT5+/+ApoE−/− mice (Figure 2C).
IMMUNOHISTOCHEMICAL QUANTIFICATION OF AORTIC ARCH
LESIONS DOES NOT REVEAL A DISCERNABLE DIFFERENCE IN
SMOOTHMUSCLE CELL OR MACROPHAGE INVESTMENT OF THE
LESION
To examine whether NFAT5 levels had an effect on lesion
composition or cellular content, we performed immunohis-
tochemistry to quantify SMC and macrophage investment of
aortic arch lesions (Figure 3). Smooth muscle alpha actin
(SMαA) and macrophage 2 (MAC2) protein identified SMCs
and macrophages, respectively, that had migrated into the lesion.
With this method of analysis, we were unable to record a sig-
nificant difference in SMC or macrophage investment of the
FIGURE 1 | Schematic of artery preparations. Mouse aortic tissues were
handled identically for both genome-wide and bone marrow transplant
atherosclerosis studies. Aortic arches were fixed and sectioned for
immunohistochemical analysis. Descending thoracic aortas were fixed,
cleaned and stained with Sudan IV for en face analysis.
lesion (Figure 3). Further cell-specific NFAT5 haploinsufficient
in vivo experiments were, therefore, required to determine how
NFAT5 deficiency in the cells of the lesion affected atherosclerosis
progression.
TRANSPLANTATION OF NFAT5 HAPLOINSUFFICIENT BONE
MARROW INHIBITS ATHEROSCLEROTIC LESION FORMATION
We sought to establish if NFAT5 levels in BM-derived cells
alone could account for the reduction in atherosclerosis
observed in NFAT5 haploinsufficient mice. To test this hypoth-
esis, we performed a BMT of NFAT5+/−ApoE−/− BM into
NFAT5+/+ApoE−/− mice. Following a 4-week recovery and 16-
week HFD, mouse aortas were prepared for analysis (Figure 1).
Sudan IV staining and en face preparation of the thoracic aorta
identified an 86% reduction in atherosclerotic lesion coverage
in mice transplanted with NFAT5+/−ApoE−/− BM (Figure 4A).
Unlike our genome-wide NFAT5 haploinsufficient atherosclerosis
studies, mice transplanted with NFAT5+/−ApoE−/− BM devel-
oped little to no lesions in the aortic arch and therefore could
not be used for immunohistochemistry-based lesion composi-
tion analysis. After 16 weeks of HFD feeding, no difference was
recorded in total cholesterol or body weight between both BMT
groups (Figure 4B).
NFAT5 DEFICIENCY IMPAIRS MACROPHAGEMIGRATION
Results from our BMT studies demonstrate that NFAT5 expres-
sion in BM-derived cells is required for atherosclerosis devel-
opment in the mouse aorta (Figure 4A). Although the BM is
comprised of many different cell types (i.e., macrophages, T-cells,
B-cells, dendritic cells, mast cells, and neutrophils), these cells
have varying degrees of involvement in atherosclerosis (Hansson
and Hermansson, 2011). Macrophages play the most dominant
role in enhancing lesion size, instability, and vascular inflamma-
tion (Moore and Tabas, 2011), which led us to question if NFAT5
expression in macrophages was required for their normal func-
tion in atherosclerosis. These functions are: (1) adhesion to ECs
in atherosclerosis-prone regions of the vasculature, (2) chemo-
tactic migration toward cytokines produced in the lesion, (3)
cytokine-stimulated proliferation, and (4) engulfment of parti-
cles. BM harvested from WT and NFAT5+/− mice was differen-
tiated into BMDMs for in vitro analysis. Our results show that
NFAT5 is not required for macrophage adhesion (Figure 5A),
proliferation (Figure 5C), or engulfment (Figure 5D), but NFAT5
is required for macrophage migration (Figure 5B). NFAT5+/−
BMDMs exhibited significantly decreased chemotactic migra-
tion in response to M-CSF stimulation compared to control WT
BMDMs (Figure 5B).
DISCUSSION
Atherosclerosis is a complex, chronic inflammatory disease.
Various BM-derived immune cells such as macrophages, B-and
T-cells, and mast cells have been implicated in atherosclerotic
development and inflammation (Hansson and Hermansson,
2011). Macrophages constitute the largest fraction of immune
cells recruited to the lesion and are responsible for the release
of inflammatory cytokines, cholesterol uptake, and lesion necro-
sis. Our studies reveal that NFAT5 expression in BM-derived cells
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FIGURE 2 | Genome-wide NFAT5 haploinsufficiency inhibits
atherosclerotic lesion formation. Mice were placed on a high fat diet for 20
weeks. (A) En face Sudan IV staining and analysis of the thoracic aorta.
(B) H&E staining and analysis of aortic arch lesions. (C) Total cholesterol and
mouse body weight were measured after 20 weeks of high fat diet feeding
(n = 7 NFAT5+/+ApoE−/− mice and 11 NFAT5+/−ApoE−/− mice, ∗p < 0.05).
alone is responsible for enhancing atherosclerosis. While it is
known that NFAT5 regulates inflammatory gene expression in
macrophages (Machnik et al., 2009; Roth et al., 2010; Buxade
et al., 2012), we show novel evidence for the NFAT5-dependent
regulation of macrophage function. We report that NFAT5 is
required forM-CSF-inducedmacrophage chemotactic migration,
which suggests that NFAT5 may play a role in M-CSF-mediated
recruitment of monocytes/macrophages into the atherosclerotic
lesion. We hypothesize that NFAT5 haploinsufficiency in vivo
may result in deficient macrophage migration into the lesion,
therefore leading to decreased macrophage uptake of choles-
terol, decreased foam cell formation, and an overall reduction in
lesion size.
Our lab has previously reported that NFAT5 is required for
SMC migration in vitro in response to platelet-derived growth
factor BB (PDGF-BB) stimulation (Halterman et al., 2011b).
PDGF-BB is a mitogen released in the vasculature following acute
vascular injury; however, PDGF-BB does not play as central a
role in chronic atherosclerosis. We were unable to measure a sig-
nificant difference in SMC investment of NFAT5+/+ApoE−/−
and NFAT5+/−ApoE−/− lesions through our method of analy-
sis, but generation of a SMC-specific NFAT5+/−ApoE−/− mouse
would provide a model to specifically determine the role of
NFAT5 in SMCs of the atherosclerotic lesion. We chose to pro-
ceed with BM transplant studies to specifically analyze how
NFAT5 deficiency in BM-derived cells impacted atherosclerotic
development.
Although undetermined, NFAT5 regulation of B- and T-cells
in atherosclerosis could also account for the drastic reduction
in lesion formation identified in NFAT5 haploinsufficient BM
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FIGURE 3 | Immunohistochemical quantification of aortic arch lesions
does not reveal a discernable difference in smooth muscle cell or
macrophage investment of the lesion. Immunohistochemical analysis of
aortic arch lesions. SMαA and MAC2 are markers for smooth muscle cells
and macrophages, respectively (n = 7 NFAT5+/+ApoE−/− mice and 11
NFAT5+/−ApoE−/− mice, bar = 0.6μm).
FIGURE 4 | Transplantation of NFAT5 haploinsufficient bone marrow
inhibits atherosclerotic lesion formation. Bone marrow transplant mice
were placed on a high fat diet for 16 weeks. (A) En face Sudan IV staining of
the thoracic aorta. (B) Total cholesterol and mouse body weight were
measured after 16 weeks of high fat diet feeding (n = 10 NFAT5+/+ApoE−/−
BM mice and 15 NFAT5+/−ApoE−/− BM mice, ∗∗∗p < 0.001).
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FIGURE 5 | NFAT5 deficiency impairs macrophage migration. Bone
marrow harvested from WT and NFAT5+/− mice was treated with M-CSF for
7 days to differentiate cells into bone marrow-derived macrophages
(BMDMs). Functional analyses were then performed. BMDMs were tested
for adhesion to TNFα-activated endothelial cells (A), M-CSF-stimulated
chemotactic migration (B), M-CSF-stimulated proliferation (C), and
engulfment of fluorescent beads (D) (n = 3−6 WT or NFAT5+/− mice,
∗p < 0.05 ∗∗p < 0.005).
transplant mice. Previous studies demonstrate that in vitro stim-
ulation of NFAT5−/− T-cells in hypertonic media results in an
imbalanced naïve/memory T-cell response (Berga-Bolanos et al.,
2010). It is, therefore, possible that mice receiving NFAT5 hap-
loinsufficient BM have decreased T-cell investment of the lesion
due to impaired T-cell memory. Further studies will be necessary
to determine the precise role of NFAT5 expression in T-cells of the
atherosclerotic lesion.
We show that NFAT5 is required for M-CSF-induced
macrophage migration, but it is unknown how M-CSF stim-
ulation regulates NFAT5 expression, activation, or cellular
localization. NFAT5 expression in macrophages has only been
identified as being regulated by toll-like receptor stimula-
tion (Buxade et al., 2012) and hypertonicity-induced acti-
vation of NFAT5 (Morancho et al., 2008; Machnik et al.,
2009). Although untested, M-CSF and other atherogenic stim-
uli may be involved in the activation of downstream kinases to
promote the phosphorylation and translocation of NFAT5 to the
nucleus. This putative mechanism could result in the NFAT5-
mediated activation of migratory genes such as Cyr61, a known
NFAT5 target gene in skeletal muscle myoblasts (O’Connor
et al., 2007). While it would be difficult to test, we specu-
late that hypertonic microenvironments could develop within
the vessel wall during atherosclerotic lesion progression, pos-
sibly due to foam cell necrosis and the subsequent release of
intracellular contents into the extracellular space. Other stud-
ies demonstrate that macrophages in a hypertonic environ-
ment increase NFAT5 expression and NFAT5 binding to the
vascular endothelial growth factor C (VEGF-C) promoter to
enhance lymphogenesis in the skin (Machnik et al., 2009).
VEGF-C is also a potent inducer of vascular angiogenesis that
stimulates intimal neovascularization (i.e., increased formation
of blood vessels within the atherosclerotic lesion) to enhance
lesion progression, macrophage apoptosis, and lesion instability
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(Nakano et al., 2005; Schmeisser et al., 2006). Therefore, small
hypertonic microenvironments within atherosclerotic lesions
could serve to activate NFAT5 in macrophages, then in
turn enhancing VEGF-C expression, angiogenesis, and lesion
development.
Together, these data provide novel insight into the NFAT5-
dependent regulation of atherosclerotic lesion development
and macrophage function. The results of these studies demon-
strate the importance of NFAT5 expression in the immune
cells associated with chronic vascular disease and pro-
vide evidence for the role of NFAT5 in inflammation and
atherosclerosis.
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